Sanofi Backs Novadiscovery In Silico Trial Platform
French Biotech Raises €2.5m
Novadiscovery has received funding from Sanofi and will support the French major’s COVID-19 efforts with its virtual JINKO clinical trial platform.
You may also be interested in...
Disruptions to clinical research during the COVID-19 pandemic has kindled a new level interest in using computer simulations to predict clinical trial outcomes. Regulatory guidance on “good simulation practices” can move things up a notch in this emerging field.
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.
Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.